421 related articles for article (PubMed ID: 16403822)
1. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
2. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
Tonella P; Flück CE; Mullis PE
Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.
Cox GN; McDermott MJ; Merkel E; Stroh CA; Ko SC; Squires CH; Gleason TM; Russell D
Endocrinology; 1994 Nov; 135(5):1913-20. PubMed ID: 7525258
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
9. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
[TBL] [Abstract][Full Text] [Related]
10. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
12. Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study.
Hansen-Pupp I; Hellström A; Hamdani M; Tocoian A; Kreher NC; Ley D; Hallberg B
Growth Horm IGF Res; 2017 Oct; 36():44-51. PubMed ID: 28934640
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
[TBL] [Abstract][Full Text] [Related]
14. Recombinant IGF-I: Past, present and future.
Bright GM
Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
[TBL] [Abstract][Full Text] [Related]
15. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
[TBL] [Abstract][Full Text] [Related]
16. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes.
Guha N; Nevitt SP; Francis M; Woodland JA; Böhning D; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2015 Aug; 100(8):3126-31. PubMed ID: 26046967
[TBL] [Abstract][Full Text] [Related]
18. Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
Hanew K; Tanaka A
J Endocrinol Invest; 2001 Jan; 24(1):1-7. PubMed ID: 11227726
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycemic and growth promoting activities of rhIGF-1 in the rat.
Clark RG; Mortensen D; Reifsynder D; Mohler M; Etcheverry T; Mukku V
Growth Regul; 1993 Mar; 3(1):50-2. PubMed ID: 7683530
[TBL] [Abstract][Full Text] [Related]
20. Safety aspects of longitudinal administration of IGF-I/IGFBP-3 complex in neonatal mice.
Hellgren G; Han W; Wang X; Löfqvist C; Hagberg H; Mallard C; Hellström A
Growth Horm IGF Res; 2011 Aug; 21(4):205-11. PubMed ID: 21696987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
